Cero Therapeutics Holdings, INC Form 4 insider transactions

Director Eric Francois was granted 1,823,278 stock options in Cero Therapeutics Holdings, Inc. with a $0.055 strike price.

CERO Therapeutics Holdings Director Rolfe Lindsey was granted 690,900 stock options exercisable at $0.055 per share.

CERO Therapeutics Holdings Director Kathleen Laporte acquired 690,900 stock options at an exercise price of $0.055, effective January 7, 2026.

CERO Therapeutics Holdings, Inc.'s Chief Development Officer, Kristen Pierce, acquired 1,612,099 stock options exercisable at $0.055 per share.

CERO Therapeutics Holdings Director Shami Patel acquired 690,900 stock options at an exercise price of $0.055, exercisable from January 7, 2026.

CERO Therapeutics Holdings Director and 10% owner Brian G. Atwood acquired 1,612,099 stock options at an exercise price of $0.055 per share.

Christopher B. Ehrlich, Chairman and CEO of CERO Therapeutics Holdings, Inc., acquired 4,530,997 stock options exercisable at $0.055 per share.

CERO Therapeutics Holdings Director Michael Byrnes acquired 690,900 stock options with an exercise price of $0.055, exercisable immediately.

CERO Therapeutics Holdings, Inc. Chief Financial Officer Andrew Kucharchuk was granted 1,162,099 stock options with an exercise price of $0.055.

CERo Therapeutics Holdings, Inc. director Kathleen LaPorte was granted 9,326 stock options with an exercise price of $0.4454, part of a larger award vesting based on time and performance conditions, alongside the filing of a Limited Power of Attorney.

CERo Therapeutics Holdings, Inc. (CERO) Director Michael Byrnes was granted 9,326 stock options with an exercise price of $0.4454, as part of a larger award, and executed a Power of Attorney for SEC compliance filings.

CERo Therapeutics Holdings, Inc. director Lindsey Rolfe was granted 9,326 stock options at an exercise price of $0.4454, with a portion vesting monthly and the remainder tied to performance conditions, as detailed in a recent SEC Form 4 filing.

Cero Therapeutics Holdings, Inc. Director Shami Patel was granted 11,693 stock options with a strike price of $0.4454, part of a larger award, as reported in a recent SEC Form 4 filing.

Christopher B. Ehlich, Chairman and CEO of CERo Therapeutics Holdings, Inc., was granted 61,843 stock options at an exercise price of $0.4454, with a portion vesting monthly and the remainder subject to performance conditions, as detailed in a recent Form 4 filing.

CERo Therapeutics Holdings, Inc. Director Brian G. Atwood was granted 122,549 stock options, vesting monthly through May 2027, as disclosed in a recent SEC Form 4 filing which also included a Limited Power of Attorney.

CERO Therapeutics Holdings, Inc.'s Chief Development Officer, Kristen Pierce, was granted 154,841 stock options with an exercise price of $0.4454, vesting through June 2027.

CERO Therapeutics Holdings, Inc. Chief Financial Officer, Andrew Albert Kucharchuk, was granted 152,500 stock options with an exercise price of $0.4454 per share, vesting through June 2027.

Director Brian Atwood reports exercising pre-funded warrants and directing the issuance of common stock to a trust, impacting his beneficial ownership in CERO Therapeutics Holdings.

Kathleen Laporte, a director at Cero Therapeutics Holdings, Inc., reported the acquisition of stock options to purchase 17,923 shares of common stock.

Director Lindsey Rolfe acquired stock options for 17,923 shares of Cero Therapeutics Holdings on March 4, 2025.

Michael Byrnes, a director of Cero Therapeutics Holdings, acquired stock options for 17,923 shares on March 4, 2025.

Director Shami Patel acquires stock options in Cero Therapeutics Holdings, Inc.

Director Brian G. Atwood acquired stock options in Cero Therapeutics Holdings, Inc. on March 4, 2025.

Christopher B. Ehrlich, CEO of Cero Therapeutics Holdings, acquired stock options for 119,486 shares on March 4, 2025.

Director Lindsey Rolfe acquired 127,500 shares of Cero Therapeutics Holdings through the vesting of a stock option.

Director Shami Patel acquires 127,500 stock options in Cero Therapeutics Holdings after the company's Board confirms performance criteria were met.

Kathleen Laporte, a director at Cero Therapeutics Holdings, Inc., exercised stock options for 127,500 shares after the company's Board of Directors confirmed the satisfaction of performance criteria.

Christopher B. Ehrlich, CEO of Cero Therapeutics Holdings, exercises stock options for 1,275,000 shares after the company's board confirmed the satisfaction of performance criteria.

Director Michael Byrnes acquired 127,500 shares of Cero Therapeutics through the vesting of a stock option.

Brian G. Atwood, a director at Cero Therapeutics Holdings, acquired 254,000 stock options after the company's Board of Directors confirmed the satisfaction of performance criteria.